Cell and Gene Therapy Business Outlook: Volume 1, Issue 14

Don't miss our new twice-monthly publication dedicated to cell and gene therapy. Cell and Gene Therapy Business Outlook offers the following:

  • Market Sizing and Forecasting of CAGT Markets
  • Executive News Summaries
  • Deals Between CAGT Companies Tracked
  • Financing
  • Trends in the Industry
  • Important Science That Will Shape Tomorrow’s Business
  • Company Profiling and Quarterly Results Summaries
  • Updates on Pipelines and Important Clinical Trials
  • Cell and Gene Therapy Tools
  • Cell and Gene Therapy CMOs
  • And More
Table of Contents
  • Untitled Chapter
  • Market Analysis
    • Focus on Cell and Gene Therapy for Liver Diseases
      • Overview of Cell and Gene Therapy for Liver Diseases
    • Market Outlook
    • Products in Development
    • Regional Analysis
    • Top Company Briefs
      • Alnylam Pharmaceuticals
      • Bristol-Myers Squibb
      • Arrowhead Pharmaceuticals
      • Steminent Biotherapeutics
  • Executive News Brief
    • Recent developments in cell and gene therapy
  • Recent Funding Deals
    • 2022 Starts with Two Hundred-Million Dollar Deals
  • Cell and Gene Therapy Market News and News Analysis
    • SalioGen Therapeutics Raises $115 Million for Gene Coding Platform
    • Synthetic Biology Company Senti Bio to Go Public with SPAC Merger
  • Cell and Gene Therapy Expert Interviews
    • INTERVIEW: Amanda Cashin, Illumina for Startups
  • Recent CGT Deal Activity
Attachments
  • pdf - KC_Vol. 1 Issue 14 - CELL AND GENE THERAPY BUSINESS OUTLOOK.pdf